SCA
DNA icon

Snowden Capital Advisors’s Ginkgo Bioworks DNA Stock Holding History

Snowden Capital Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-250
Closed -$16.9K – 1157
2022
Q4 		$16.9K Buy
+250
New +$23K ﹤0.01% 1122

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Snowden Capital Advisors's DNA Position: Q1 2023 in Review

Snowden Capital Advisors sold out of Ginkgo Bioworks (DNA) in Q1 2023, closing a stake of 250 shares — an estimated $16.9K sold.

Snowden Capital Advisors first reported a position in DNA in Q4 2022 and held it in 1 quarter. The position peaked at $16.9K in Q4 2022. 313 funds tracked by Wall St. Rank hold DNA as of Q1 2023.

  • Snowden Capital Advisors reported no remaining Ginkgo Bioworks position as of Q1 2023 after selling out during the quarter.
  • Snowden Capital Advisors sold 250 Ginkgo Bioworks shares in Q1 2023, an estimated $16.9K.
  • Snowden Capital Advisors first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 1 quarter.
  • Snowden Capital Advisors's Ginkgo Bioworks position peaked at $16.9K in Q4 2022.
  • 313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2023.

Based on Snowden Capital Advisors's 13F filing for Q1 2023, filed 15 May 2023.